Vanguard Therapeutics, Inc. is an early stage California company that is developing an orally absorbable cell adhesion-blocking drug for the prophylactic therapy of sickle cell disease. Stephen H. Embury, M.D. is our founder. Dr. Embury’s 26-year career on the faculty at UCSF and ten years experience in the pharmaceutical industry has been focused on sickle cell disease. Our program is based on the knowledge that clinical problems of sickle cell disease are the result of abnormal blood flow and that adhesion of sickle red blood cells to the vascular endothelium is fundamental to the abnormal blood flow. P-selectin on vascular endothelial cells is central to sickle red blood cell adhesion, and our parent compound effectively blocks P-selectin. With support of two phase-I SBIR grants from the NIH we are addressing the development of reliable assays for our parent compound and the identification of a superior fraction of that compound for use as our active pharmaceutical ingredient in commercial development. We currently are operating with a bare-bones minimum of active employees and a group of advisors and consultants who are leaders in the legal, scientific, pharmaceutical, and sickle cell disease fields.
San Francisco, CA